A 5-aminosalicylic acid (5-ASA) drug switch program switching from 5-ASA to sulfasalazine was instituted for insured patients with ulcerative colitis. Unanticipated barriers limited the number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback